DOCSLIB.ORG

CED 2014 Innovators Report Hires

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CED 2014 Innovators Report Hires INNOVATORS REPORT 2013 Trends in North Carolina Entrepreneurship 2013 IPO WATCH 226 NATIONAL 9 STATEWIDE 1. Aerie Pharmaceuticals 26 2. ChannelAdvisor SOUTHEAST 3. Chimerix 4. Heat Biologics 5. LipoScience 6. Ply Gem Holdings 7. Quintiles 8. Regado Biosciences 9. Stock Building Supply REPORT SOURCES: CED, National Venture Capital Association (NVCA), North Carolina Biotechnology Center, Ernst & Young, PricewaterhouseCoopers, SBIR.gov The Innovators Report is made possible by generous gifts to the CED Annual Fund. Thank you to our many supporters! For more information on how to contribute, please visit www.cednc.org/donate. MAJOR MERGERS & NC EVENTS ACQUISITIONS* DSM Pharmaceuticals Patheon $2.6 billion Santarus Salix Pharmaceuticals $2.6 billion COMPANY PRA International Kolberg, Kravis & Roberts $1.3 billion MILESTONES Solstas Lab Partners Quest Diagnostics $570 million Medicago Mitsubishi Tanabe Pharma $357 million Recognized as Advanced Liquid Logic Illumina $96 million 50 million Named Cracks a “Disrupter” sponsored 2013 Top 50 for the wireless Exam Design Pearson VUE app installs Fierce in Digital industry by Top 15 Health Entrepreneur Magazine Geomagic 3D Systems GrassRoots Biotechnology Monsanto Novella Clinical Quintiles Secure Enterprise Computing Agio Technology Axial Republic Appia Scioderm Exchange Wireless Tekelec Oracle ACQUIRED ACQUIRED BY *Partial listing DEALS & PARTNERSHIPS Signs up Yahoo! Sports, Bloomberg, CBS and Gannett $70 million deal with Toyama Chemical Company and a $58 million BARDA contact CHATHAM THERAPEUTICS Signs major deal with Baxter International Signs deal with Sanofi & Horizon Pharma 1 of 15 Google “Premier” Partners Lands $40 million contract with FDA 260 TOTAL INVESTMENTS 1 LIFE SCIENCE ..................$275,486,045 34 Equity...................................$244,728,800 Grants/Awards............................$30,757,245 Biopharma: 62 deals • Medtech: 49 deals • Other: 23 deals TECH .........................$116,873,094 Equity.....................................$116,139,075 106 Grants/Awards................................$508,230 Crowdfunding................................$225,789 ADVANCED MANUFACTURING.....$68,709,235 Equity.......................................$68,039,235 19 Grants/Awards..................................$670,000 OTHER Equity...............................$173,107 1 TOTAL MONEY RAISED $461,241,481 WHO’S INVESTING: 108 TOTAL UNIQUE FUNDERS* 3G Capital Hatteras Venture Partners MCG Capital Corporation North Carolina Postcode Lottery ABS Capital Partners Healthbox Medimmune LLC Biotechnology Center Green Challenge Acadia Woods Partners HIG Capital Michael J. Fox Foundation Novak Biddle Venture Partners PTV Sciences Acorn Innovestments IDEA Fund Partners Morgenthaler Ventures Novartis Venture Funds QuestMark Partners, LP Aisling Capital IMAF-Cape Fear Morningside Technologies Novel TMT Ventures Ltd Relevance Capital Inc. Allscripts Open App Challenge IMAF-RTP Mountain Group Capital NSF Revolution Growth Fund Alta Partners Independence Blue Cross Pappas Ventures Rex Health Ventures American Heart Association’s Science 3 CANADA River Cities Capital Funds & Technology Accelerator Program Riverside Partners ARCH Venture Partners MIDWEST NORTHEAST RiverVest Venture Partners Bay Area Lyme Foundation RTP Capital Biogenerator and The Helix Fund S-Grupp Capital Management of St. Louis, Missouri SJF Ventures BlueTree Allied Angels Southern Capitol Ventures Brenden Family Growth Fund Spray Venture Partners Broadview Ventures 1 SEATTLE Sumitomo Corp Bull City Venture Partners 10 24 Synergy Life Science Partners Camden Partners Syngenta Ventures Canaan Partners CALIFORNIA 10 26 3 ASIA NORTH CAROLINA EUROPE Capital Communications CDPQ Inc. 7 Care Capital Carmel Ventures CDP Capital Private Equity 10 Tech Stars Chicago Contender Capital Technology Partners Domain Associates Terracap Ventures DreamIT Ventures 14 The 3x5 Special Opportunity Fund E Merge SA The Aurora Funds FCA Venture Partners SOUTHEAST The Missouri Technology FINISTERE VENTURES Corporation FirstMark Capital Triangle Angel Partners Fletcher Spaght Ventures Innotech Advisers MID-ATLANTIC Triangle Startup Factory Forbion Capital Partners Intel Capital Corp Triathlon Medical Ventures Fortis Capital Holdings Intersouth Partners TVC Capital Fulcrum Equity Partners Life Science Angels MPM Capital LLC Patient-Centered Outcomes TVM Capital GmbH Gemini Israeli Ventures Lookout Capital MSouth Equity Partners Research Institute UNC Carolina Kickstart Globespan Capital Partners Lord Baltimore Capital NCIDEA Pearl Street Venture Funds Commercialization Award Grotech Ventures Lumira Capital Corp New Enterprise Associates Piedmont Angel Network Ventech SA Harbert Venture Partners Madison River Ventures NIH Plexus Capital Wakefield Group Harris & Harris Group Massey Burch Capital Corporation North Atlantic Capital Polaris Partners WRD Capital *Institutional investors only.
Load more

Recommended publications
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • RESI Boston Program Guide 09-26-2017 Digital
    SEPTEMBER 26 , 2017 BOSTON, MA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESIBOS17 | RESIConference.com | Boston Marriott Copley Place FLOOR PLAN Therapeutics Track 2 Investor Track 3 & track4 Track 1 Device, Panels Workshops & Diagnostic & HCIT Asia Investor Panels Panels Ad-Hoc Meeting Area Breakfast & Lunch DINING 29 25 30 26 31 27 32 28 33 29 34 30 35 Breakfast / LunchBreakfast BUFFETS 37 28 24 27 23 26 22 25 21 24 20 23 19 22 exhibit hall 40 15 13 16 14 17 15 18 16 19 17 20 18 21 39 INNOVATION 14 12 13 11 12 10 11 9 10 8 9 7 8 EXHIBITORS CHALLENGE 36 38 FINALISTS 1 1 2 2 3 3 4 4 5 5 6 6 7 Partnering Check-in PARTNERING Forum Lunch BUFFETS Breakfast / Breakfast RESTROOM cocktail reception REGISTRATION content Welcome to RESI - - - - - - - - - - - - - - - 2 RESI Agenda - - - - - - - - - - - - - - - - - - 3 BOSTON RESI Innovation Challenge - - - - - - - 5 Exhibiting Companies - - - - - - - - - - 12 Track 1: Therapeutics Investor Panels - - - - - - - - - - - - - - - 19 Track 2: Device, Diagnostic, & HCIT Investor Panels - - - - 29 Track 3: Entrepreneur Workshops - - - - - - - - - - - - - - - - - - 38 Track 4: Asia-North America Workshop & Panels - - - - - - 41 Track 5: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - 45 Sponsors & Media Partners - - - - - - - - - - - - - - - - - - - - - - - 46 1 welcome to resi On behalf of Life Science Nation (LSN) and our title sponsors WuXi AppTec and Johnson & Johnson Innovation JLABS, I would like to thank you for joining us at RESI Boston. LSN is very happy to welcome you all to Boston, the city where it all began, for our 14th RESI event.
    [Show full text]
  • DENVER CAPITAL MATRIX Funding Sources for Entrepreneurs and Small Business
    DENVER CAPITAL MATRIX Funding sources for entrepreneurs and small business. Introduction The Denver Office of Economic Development is pleased to release this fifth annual edition of the Denver Capital Matrix. This publication is designed as a tool to assist business owners and entrepreneurs with discovering the myriad of capital sources in and around the Mile High City. As a strategic initiative of the Denver Office of Economic Development’s JumpStart strategic plan, the Denver Capital Matrix provides a comprehensive directory of financing Definitions sources, from traditional bank lending, to venture capital firms, private Venture Capital – Venture capital is capital provided by investors to small businesses and start-up firms that demonstrate possible high- equity firms, angel investors, mezzanine sources and more. growth opportunities. Venture capital investments have a potential for considerable loss or profit and are generally designated for new and Small businesses provide the greatest opportunity for job creation speculative enterprises that seek to generate a return through a potential today. Yet, a lack of needed financing often prevents businesses from initial public offering or sale of the company. implementing expansion plans and adding payroll. Through this updated resource, we’re striving to help connect businesses to start-up Angel Investor – An angel investor is a high net worth individual active in and expansion capital so that they can thrive in Denver. venture financing, typically participating at an early stage of growth. Private Equity – Private equity is an individual or consortium of investors and funds that make investments directly into private companies or initiate buyouts of public companies. Private equity is ownership in private companies that is not listed or traded on public exchanges.
    [Show full text]
  • The 2018 Preqin Private Capital Fund Terms Advisor – Sample Pages
    THE 2018 PREQIN PRIVATE CAPITAL FUND TERMS ADVISOR – SAMPLE PAGES 1. EXECUTIVE SUMMARY Fig. 1.1: Annual Global Private Capital Fundraising, 2000 - 2018 YTD (As at June 2018) 2,500 2,307 2,340 2,044 1,945 2,000 1,855 1,632 1,642 1,659 nvestors remain satisfied with private The opaque nature of private capital 1,570 1,500 1,424 capital, with fundraising in 2017 surpassing investments makes it consistently difficult 1,333 I 1,183 1,118 the $800bn mark for the first time on record for a consensus or benchmark to be reached 1,000 921 (Fig. 1.1). More capital was also distributed across the industry. Unique features change 811 768 848 667 688 712 669 700 across fewer funds, resulting in the average the profile of a given fund, and greatly 605 583 547 587 575 500 387 451 fund size growing to $507mn in 2017 affect how fees are set out and levied. 2017 365 327 322 274 239 172 222 compared to $411mn in 2016. This suggests once again saw greater movement towards 135 106 that competition in the market remains transparency throughout the industry, as 0 fierce and that managers will need to ensure voiced by many investors interviewed by 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 they are continually providing satisfaction Preqin during the course of the year. It is to and striving for an alignment of interests clear at this point that the momentum is 2018 YTD Year of Final Close with their LPs.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Mbamission's Insider's Guide
    mbaMission’s Insider’s Guide The Wharton School University of Philadelphia Philadelphia, PA 2019–2020 presented by Applying to Business School? mbaMission is your partner in the process! Our team of dedicated, full-time admissions experts has helped thousands of applicants get into their dream MBA programs. These skilled storytellers and MBA graduates will work one-on-one with you to help you discover, select, and articulate your unique stories and stand out from the crowd. Why mbaMission? 15+ years of experience advising Ranked number one firm by GMAT tens of thousands of business Club and Poets&Quants school applicants Exclusively recommended by Extensive, unparalleled library of Services available for all stages of Manhattan Prep since 2009 supplementary content the application process Schedule a free, 30-minute consultation at www.mbamission.com/consult, and start getting answers to all your MBA admissions questions! +1-646-485-8844 [email protected] www.mbamission.com About mbaMission With our collaborative, full-time team of experienced advisors, mbaMission has elevated and professionalized the world of MBA admissions consulting, earning the exclusive recommendation of the world’s leading GMAT prep firms, Manhattan Prep and Kaplan GMAT, and hundreds more verified five-star reviews on GMAT Club than any other such firm. mbaMission prides itself on its high-touch client engagement model and robust library of free content that includes these Insider’s Guides as well as our Complete Start-to-Finish MBA Admissions Guide. Having already helped thousands of aspiring MBAs from around the world gain entry into elite US and international business schools, mbaMission continues to grow and improve in our quest to “graduate” additional classes of satisfied clients.
    [Show full text]
  • Growthink Research 2004 Annual Healthcare Venture Capital Report
    EXECUTIVE SUMMARY & SAMPLE PAGES 2004 ANNUAL REPORT Healthcare Venture Capital Report growthink RESEARCH $5.8 Billion Invested 470 Company Profiles 525 Investor Profiles www.growthinkresearch.com growthink⏐RESEARCH Executive Summary Introduction Four hundred seventy (470) privately held biotechnology, pharmaceutical, medical device and other healthcare companies raised $5.8 billion in venture capital in 2003. These companies received over 30% of the total dollars invested, up from 26% in 2002. Investments in this sector picked up considerably in the latter half of 2003 following the successful IPOs of venture-backed companies such as Acusphere, CancerVax and Myogen. With more healthcare companies slated to go public in 2004, the industry is optimistic for an extraordinary year. Total U.S. Funding by Sector – 2003 Dollars Pct. of No. of Pct. of Average Invested Total Cos. Total Deal Size Connectivity $6,817,557,000 35.8% 576 31.0% $11,836,036 Healthcare $5,813,374,000 30.5% 470 25.3% $12,368,881 Business Software & Services $3,962,150,000 20.8% 542 29.1% $7,310,240 Other $1,438,194,000 7.6% 161 8.7% $8,932,882 E-Content & Commerce $998,950,000 5.2% 111 6.0% $8,999,550 Totals: $19,030,225,000 100.0% 1860 100.0% $10,231,304 Regions Bay Area companies led the nation in raising capital, receiving 23% of the dollars invested. CoTherix (Belmont, CA) and Corgentech (South San Francisco, CA) led the region, which was home to 96 healthcare ventures that raised $1.4 billion. CoTherix, a biopharmaceutical company that develops and commercializes therapeutics for life-threatening diseases, completed a $55 million Series C round.
    [Show full text]
  • The View Beyond Venture Capital
    BUILDING A BUSINESS The view beyond venture capital Dennis Ford & Barbara Nelsen Fundraising is an integral part of almost every young biotech’s business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital. re you a researcher looking to start a Why and how did the funding landscape During the downturns, it quickly became Anew venture around a discovery made change? apparent that entrusting capital to third-party in your laboratory? Perhaps you have already The big changes in the life science investor alternative fund managers was no longer an raised some seed money from your friends landscape start with the venture capitalist effective strategy, and investors began to with- and family and are now seeking funds to sus- (VC). In the past, venture capital funds were draw capital. The main reason for the with- tain and expand your startup. In the past, the typically capitalized by large institutional drawal (especially from VCs in the early-stage next step on your road to commercialization investors that consisted of pensions, endow- life science space) was generally meager returns would doubtless have been to seek funding ments, foundations and large family offices across the asset class; despite the high risk and from angels and venture capital funds; today, with $100 million to $1 billion in capital long lockup periods that investors accepted in however, the environment for financing an under management. Traditionally, the major- return for a promise of premium performance, early-stage life science venture looks strik- ity of these institutions maintained a low-risk, VCs were often not returning any more capital ingly different from that familiar landscape low-return portfolio of stocks and bonds that than investors would have earned by making of past decades.
    [Show full text]
  • Clear Route to Phase Iib
    REPRINT FROM MARCH 24, 2008 BioCentury ® THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint Page 1 of 9 Ebb & Flow Focus Clear route to Phase IIb By Mike Ward investment with the potential to follow on up to a total of $30- Senior Editor $40 million per company.” Although big series A rounds have become increasingly Indeed, the average size of the 10 most recent rounds Phase4 commonplace, the recent deal for Albireo AB, expected to Ventures has participated in is a touch over $50 million. This is reach $40 million, reflects business as usual for Nomura more than two and a half times the average biotech venture Phase4 Ventures. The London firm has taken an aggres- round over the same period. sive approach to investing its parent’s money in biotech, Phase4 has participated in three series A rounds in the past characterized by large financing rounds geared to providing three years in which the syndicates committed a total of $162 a clear route to Phase IIb data, underpinned by international million to the three companies. syndication. The firm focuses primarily on investment in clinical stage Phase4’s story is one of increasing scale, with rounds companies and as a result has a portfolio that is heavily biased mounting in size from 1999 until the VC toward the U.S. Over 75% of the compa- hit its stride in 2004. Since then, the firm nies Phase4 invests in are in Phase I or has usually taken the lead in $1.3 billion “You need to bring enough II, with an average holding time of about worth of venture rounds.
    [Show full text]
  • Fresh Money 2013-Q4 Copyright
    Fresh Money 2013-Q4 http://jaycaplan.com/ Date VC/PE Website Headline Location Techrockies Reports that Boulder Ventures Is To Raise $100M 12/26/13 Boulder Ventures http://www.boulderventures.com/ Sixth Fund Boulder, CO Boston-based private equity firm Mansa Capital Management Raises $50M to invest in healthcare information technology (HCIT) and services companies that help to contain healthcare 12/21/13 Mansa Capital Management http://www.mansacapital.com/ costs and improve clinical outcomes Boston PE Firn Welsh, Carson, Anderson & Stowe Raising $3B 12th PE Fund for growth-oriented companies in the healthcare and 12/13/13 Welsh, Carson, Anderson & Stowe http://www.welshcarson.com/ information/business services industries New York 12/21/13 Economic Development Corp. http://www.nycedc.com/press-release/deputy-mayor-steel-and-nycedc-announce-two-new-initiatives-dramatically-grow-citysWSJ: New York City to Start $50M Venture Fund for Biotech New York Growth PE Firm Great Point Partners closes $215M health care 12/21/13 Great Point Partners http://www.gppfunds.com/ investment Fund II Greenwich, CT 12/13/13 Investor AB http://www.investorgrowthcapital.com/ Investor Growth Capital Ends Venture Investing New York Biomark Capital Forms $200M VC fund by Splitting Off from 12/3/13 Biomark Capital http://biomarkcapital.com/ Burrill Capital Greenwich, CT 12/3/13 5AM Venture Management http://5amventures.com/ 5AM Ventures Raises $250M Fourth Life Science Venture Fund Menlo Park CA, Boston MA Gilde Healthcare closes €145 million ($200 million) Utrecht, The Netherlands, 11/26/13 Gilde Healthcare http://www.gildehealthcare.com/ transatlantic growth capital fund Cambridge, MA Edmond de Rothschild Investment Partners Closes 4th €192M 11/4/13 Edmond de Rothschild Investment Partnershttp://www.edmond-de-rothschild.fr/En/edrip/Pages/default.aspxEuropean Life Science Fund Paris, France Palo Alto, CA, Boston, MA, Venture Debt Leader Hercules Technology Growth Capital Westminster, CO, McLean, VA, 11/4/13 Hercules Technology Growth Capital, http://www.htgc.com/Inc.
    [Show full text]
  • Appendix D - Securities Held by Funds October 18, 2017 Annual Report of Activities Pursuant to Act 44 of 2010 October 18, 2017
    Report of Activities Pursuant to Act 44 of 2010 Appendix D - Securities Held by Funds October 18, 2017 Annual Report of Activities Pursuant to Act 44 of 2010 October 18, 2017 Appendix D: Securities Held by Funds The Four Funds hold thousands of publicly and privately traded securities. Act 44 directs the Four Funds to publish “a list of all publicly traded securities held by the public fund.” For consistency in presenting the data, a list of all holdings of the Four Funds is obtained from Pennsylvania Treasury Department. The list includes privately held securities. Some privately held securities lacked certain data fields to facilitate removal from the list. To avoid incomplete removal of privately held securities or erroneous removal of publicly traded securities from the list, the Four Funds have chosen to report all publicly and privately traded securities. The list below presents the securities held by the Four Funds as of June 30, 2017. 1345 AVENUE OF THE A 1 A3 144A AAREAL BANK AG ABRY MEZZANINE PARTNERS LP 1721 N FRONT STREET HOLDINGS AARON'S INC ABRY PARTNERS V LP 1-800-FLOWERS.COM INC AASET 2017-1 TRUST 1A C 144A ABRY PARTNERS VI L P 198 INVERNESS DRIVE WEST ABACUS PROPERTY GROUP ABRY PARTNERS VII L P 1MDB GLOBAL INVESTMENTS L ABAXIS INC ABRY PARTNERS VIII LP REGS ABB CONCISE 6/16 TL ABRY SENIOR EQUITY II LP 1ST SOURCE CORP ABB LTD ABS CAPITAL PARTNERS II LP 200 INVERNESS DRIVE WEST ABBOTT LABORATORIES ABS CAPITAL PARTNERS IV LP 21ST CENTURY FOX AMERICA INC ABBOTT LABORATORIES ABS CAPITAL PARTNERS V LP 21ST CENTURY ONCOLOGY 4/15
    [Show full text]
  • The State of Growth Equity for Minority Business: a River of Capital Flowing Past Our Communities
    The State of Growth Equity for Minority Business | 1 The State of Growth Equity for Minority Business: A river of capital flowing past our communities Marlene Orozco and Eutiquio “Tiq” Chapa The State of Growth Equity for Minority Business | 2 The NAIC (www.naicpe.com) was formed in 1971 as About this White Paper the American Association of MESBICs (AAMESBIC), Inc., under President Richard M. Nixon’s Black Capital- ism program, which sought to ease access to capital The National Association of Investment for diverse business. During the 1980s, AAMESBIC Companies, Inc. (NAIC) commissioned this report lobbied successfully for legislation that would allow alongside the report by Lawrence C. Manson, Jr., diverse firms to repurchase the preferred stock from “Access to Capital: Accelerating Growth of Diverse- the U.S. Small Business Administration (SBA) while and Women-Owned Businesses,” as part of a grant raising funds that were not SBA regulated. AAMESBIC from the Minority Business Development Agency firms began approaching pension funds and other (MBDA), an agency within the United States Depart- institutional investors to raise larger pools of capital. ment of Commerce. The grant seeks to facilitate the aggregation and deployment of $1 billion in growth In the next decade, the organization changed its name equity capital to ethnically Diverse- and Women- to the National Association of Investment Companies, Owned Business Enterprises (DWBEs). Inc. as most members had turned from reliance on the SBA to become independent, institutional private equi- ty firms. Today, the NAIC has a membership of more In this report, Marlene Orozco, Chief Executive Officer than 80 diverse private equity and hedge fund firms of Stratified Insights, LLC, a premier research managing more than $165 billion in assets.
    [Show full text]